Full Description

Allergan, Inc., incorporated in 1977, is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics and medical devices. The Company is engaged in discovering, developing and commercializing specialty pharmaceutical, medical device and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets in more than 100 countries globally. In January 2007, the Company completed the acquisition of Groupe Corneal Laboratoires (Corneal). In October 2007, the Company completed the acquisition of Esprit Pharma Holding Company, Inc. (Esprit). In July 2008, the Company acquired the Aczone (dapsone) gel 5% from QLT USA, Inc. (QLT), a wholly owned subsidiary of QLT Inc. The Company operates in two business segments: specialty pharmaceuticals and medical devices.

Specialty pharmaceuticals

The specialty pharmaceuticals segment produces a broad range of pharmaceutical products, including: ophthalmic products for chronic dry eye, glaucoma therapy, ocular inflammation, infection and allergy; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, other prescription and over-the-counter skin care products for the eye lash products, and urologics products.

The Company develops, manufactures and markets a range of prescription and non-prescription products designed to treat diseases and disorders of the eye, including chronic dry eye, glaucoma, inflammation, infection and allergy. Restasis is the prescription therapy for the treatment of chronic dry eye globally. Prolacria is the treatment for to relieve the signs of chronic dry eye by rehydrating conjunctival mucosa and increasing non-lacrimal tear component production.

The artificial tears products, including the Refresh and Optive brands, treat dry eye symptoms, including irritation and dryness due to pollution, computer use, aging and other causes. Refresh is the over-the-counter artificial tears brand in the United States and includes a range of preserved and non-preserved drops, as well as ointments to treat dry eye symptoms. The Optive brand, including Optive Lubricant Eye Drops and OptiveTM Sensitive Preservative-Free Lubricant Eye Drops, provides a dual-action formula to lubricate the surface of the eye and hydrate the eye at a cellular level to relieve dry eye symptoms. The Company’s products for the treatment of glaucoma includes the Lumigan (bimatoprost ophthalmic solution) 0.03%, or Lumigan, Alphagan (brimonidine tartrate ophthalmic solution) 0.2%, or Alphagan, Alphagan P (brimonidine tartrate ophthalmic solution) 0.15%, or Alphagan P 0.15%, Alphagan P (brimonidine tartrate ophthalmic solution) 0.1%, or Alphagan P 0.1%, Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, or Combigan and Ganfort (bimatoprost/timolol maleate ophthalmic solution) .

The Company’s ophthalmic anti-inflammatory product is the Acular (ketorolac ophthalmic solution) 0.5%, or Acular. Acular is indicated for the temporary relief of itch associated with seasonal allergic conjunctivitis, the inflammation of the mucus membrane that lines the inner surface of the eyelids, and for the treatment of post-operative inflammation in patients who have undergone cataract extraction. The Company has launched the Zymar for the treatment of the bacterial conjunctivitis.

The neuromodulator product, Botox has been approved by the United States Food and Drug Administration (FDA) to treat a variety of medical conditions, as well as for the aesthetic use. In many countries outside of the United States, Botox is also approved for treating hemifacial spasm, pediatric cerebral palsy and post-stroke focal spasticity. The FDA has approved Botox for the temporary improvement in the appearance of moderate to severe glabellar lines in adult men and women age 65 or younger.

The skin care product lines focus on the acne, psoriasis, physician-dispensed skin care and eyelash growth markets, particularly in the United States and Canada. The Aczone (dapsone) gel 5%, approved for sale in both the United States and Canada, is indicated for the treatment of acne vulgaris in patients 12 and older. Aczone contains the FDA-approved chemical entity (dapsone) for acne treatment since Tazorac (tazarotene) gel was approved in 1997. The Company launched the Aczone in the United States in November 2008.

Azelex cream is approved by the FDA for the topical treatment of mild to moderate inflammatory acne and is licensed from Intendis GmbH (Intendis), a division of Bayer Schering Pharma AG. The Company markets the Azelex cream primarily in the United States. The Company co-promoted Finacea (azelaic acid) gel 15%, or Finacea, a topical rosacea treatment, with Intendis through collaboration with Intendis that ended by its terms in February 2008.

The Company markets the Tazorac (tazarotene) gel in the United States for the treatment of acne and plaque psoriasis, a chronic skin disease characterized by dry red patches. It also market a cream formulation of Tazorac in the United States for the topical treatment of acne and for the treatment of psoriasis.

The product Avage (tazarotene) cream is indicated for the treatment of facial fine wrinkling, mottled hypo- and hyperpigmentation (blotchy skin discoloration) and benign facial lentigines (flat patches of skin discoloration) in patients using a comprehensive skin care and sunlight avoidance program. The Company launched the Avage in the United States in January 2003.

In October 2008, the Company launched the Clinique Medical, a new line of science-based skin care products that complement in-office aesthetic procedures affecting the skin. The Company develops and markets the glycolic acid-based skin care products. In April 2007, the Company launched the Vivite, an advanced anti-aging skin care line that uses the GLX Technolog, creating a highly specialized blend of glycolic acid and natural antioxidants. The Company markets the Vivité line of skin care products to physicians in the United States. Latisse (bimatoprost ophthalmic solution) 0.03%, or Latisse is the FDA-approved prescription treatment of eyelash hypotrichosis, or inadequate eyelashes. The Company is engaged in the marketing of Sanctura (trospium chloride), or Sanctura, a twice-a-day anticholinergic approved for the treatment of overactive bladder (OAB).

Medical Devices Segment

The breast implants consist of a silicone elastomer shell filled with either a saline solution or silicone gel with varying degrees of cohesivity. The Company markets the breast implants under the trade names Natrelle, Inspira, McGhan and CUI and the trademarks BioCell, MicroCell, BioDimensional and Inamed.

The Company sells breast implants in the United States and globally for use in breast augmentation, revision and reconstructive surgery. The United States market is the primary market for the saline breast implants. It sells the silicone gel breast implants in the United States and worldwide for use in breast augmentation, revision and reconstructive surgery. The Company also sells a line of tissue expanders for breast reconstruction and as an alternative to skin grafting to cover burn scars and correct birth defects.

The Company develops, manufactures and markets dermal filler products designed to improve facial appearance by smoothing wrinkles and folds. The primary facial aesthetics products are the Juvéderm dermal filler family of products, Zyderm and Zyplast and CosmoDerm and CosmoPlast.

The Juvéderm dermal filler family of products, including Juvéderm, Hydrafill and Surgiderm, are developed using the Hylacross technology, a manufacturing process that results in a smooth consistency gel formulation. This technology is based on the delivery of a homogeneous gel-based hyaluronic acid, as opposed to a particle gel-based hyaluronic acid technology, which is used in other hyaluronic acid dermal filler products.

Zyderm and Zyplast dermal fillers are injectable formulations of bovine collagen. The Zyderm family of dermal fillers is formulated for people with fine line wrinkles or superficial facial contour defects. Zyderm and Zyplast dermal fillers require a skin test, with a requisite 30-day period to observe the possibility of allergic reaction in the recipient. Both of these products are formulated with lidocaine. Zyderm and Zyplast are approved for marketing in the United States and Europe.

CosmoDerm and CosmoPlast dermal fillers are a line of injectable human skin-cell derived collagen products. CosmoDerm and CosmoPlast dermal fillers are formulated for people with fine line wrinkles or superficial facial contour defects. CosmoDerm and CosmoPlast implants do not require a skin test pre-treatment. Both of these products are formulated with lidocaine. CosmoDerm and CosmoPlast are approved for marketing in the United States, Canada and a number of European countries.

The Company develops, manufactures and markets several medical devices for the treatment of obesity. The principal product in this area is the Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity and is used as an alternative to more invasive procedures such as gastric bypass surgery or stomach stapling. The Lap-Band System is an adjustable silicone elastomer band that is laparoscopically placed around the upper part of the stomach through a small incision, creating a small pouch at the top of the stomach. The new pouch fills faster, making the patient feel full sooner and, because the adjustable component of the band slows the passage of food, patients retain a feeling of fullness for longer periods of time. In addition to the anatomic effect of the pouch, data also suggests that patients with a properly adjusted band are less hungry due to neurological feedback to the brain.

The EasyBand, like the Lap-Band System, is implanted laparoscopically through a small incision. Clinical benefits of the EasyBand are similar to the Lap-Band System’s clinical benefit, except that the EasyBand’s adjustments are done telemetrically rather than hydraulically, allowing for greater ease in adjustments and greater patient comfort. The Company also sells the Orbera Intragastric Balloon System, which is a fixed-term weight loss therapy designed for use with overweight patients. Contigen is the collagen product used for treatment of urinary incontinence due to intrinsic sphincter deficiency.

The Company competes with Alcon Laboratories, Inc., Bausch & Lomb Incorporated, Pfizer Inc., Novartis AG, Merck & Co., Inc., Falcon Pharmaceuticals, Ltd., Solstice Neurosciences Inc., Mentor Corporation, Sanofi-Aventis, Galderma, Medicis Pharmaceutical Corporation, Stiefel Laboratories, Inc., Schering-Plough Corporation, Johnson & Johnson, Obagi Medical Products, Inc., L’Oreal Group, SkinMedica, Inc., Valeant Pharmaceuticals International, Pfizer Inc., Watson Pharma Inc., Novartis Pharmaceuticals Corporation, the Proctor & Gamble Company, Astellas Pharma US, Inc. and GlaxoSmithKline plc and Ethicon Endo-Surgery, Inc.